Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.

Clinical genitourinary cancer·2026
Same author

CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.

Frontiers in immunology·2026
Same author

Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions.

Medicina (Kaunas, Lithuania)·2026
Same author

Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Facing death: the last drawings of a woman with breast cancer at the end of life.

NPJ breast cancer·2026
Same author

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients.

Scientific reports·2026

Related Experiment Video

Updated: May 23, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Lymphoproliferative disorders in multiple primary cancers.

Umut Demirci1, Nuriye Ozdemir, Mustafa Benekli

  • 1Ataturk Education and Research Hospital, Ankara, Turkey. drumutdemirci@gmail.com

Asian Pacific Journal of Cancer Prevention : APJCP
|April 17, 2012
PubMed
Summary

Cancer survivors face higher risks of secondary cancers, including lymphoproliferative disorders (LPD). This study found diffuse large B cell lymphoma most common among LPD in patients with multiple primary cancers.

Related Experiment Videos

Last Updated: May 23, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Oncology
  • Hematology
  • Cancer Epidemiology

Background:

  • Cancer survivors have an elevated risk of developing second primary cancers.
  • Lymphoproliferative disorders (LPD) are common neoplasms that can manifest as primary or subsequent malignancies.
  • Understanding the patterns of metachronous or synchronous LPD in patients with multiple primary cancers is crucial for risk stratification and management.

Purpose of the Study:

  • To analyze the incidence and characteristics of lymphoproliferative disorders (LPD) in patients diagnosed with multiple primary cancers.
  • To identify the types of LPD and associated solid tumors occurring as subsequent malignancies.
  • To investigate the temporal relationship between primary and secondary LPD diagnoses.

Main Methods:

  • A retrospective analysis of 242 patients with multiple primary cancers was conducted between 2001 and 2010.
  • Lymphoproliferative disorders (LPD) were assessed in these patients.
  • Patient data including age, cancer type, treatment history (chemotherapy, radiotherapy), and follow-up duration were analyzed.

Main Results:

  • Lymphoproliferative disorders (LPD) were detected in 49 (20.2%) of the patients.
  • Diffuse large B cell lymphoma was the most frequent LPD (n=16), followed by breast cancer (n=9) and lung cancer (n=6) as subsequent cancers.
  • The median follow-up was 70 months, with second malignancies diagnosed at a median of 51 months and third malignancies at 18 months post-primary diagnosis.

Conclusions:

  • Diffuse large B cell lymphoma is the most common lymphoproliferative disorder (LPD) observed in patients with multiple primary cancers.
  • While breast and lung cancers are frequent solid tumors in LPD survivors, DLBCL is the predominant LPD.
  • These findings highlight the importance of monitoring for specific LPDs in cancer survivors with multiple primary diagnoses.